Objective To observe the clinical effect and adverse reactions of pramipexole in patients with Parkinson's disease after cerebral infarction. Methods 86 patients with Parkinson's disease after cerebral infarction treated in our hospital from February 2016 to June 2018 were randomly divided into control group and observation group, with 43 cases in each group. Both groups were treated with basic therapy such as improvement of circulation and anticoagulation. The control group was treated with levodopa on the basis of basic treatment. The patients in the observation group were treated with pramipexole on the basis of basic treatment. Both groups were treated for 8 weeks. The clinical efficacy of the two groups, UPDRSⅡ,Ⅲ scores before and after treatment, serum C-reactive protein(CRP), interleukin-6 (IL-6) and other inflammatory factors and adverse reactions during the treatment were compared. Results The total clinical effective rate of the observation group was significantly higher than that of the control group(P<0.05). The UPDRS Ⅱ and Ⅲ scores of the two groups were significantly lower after treatment(P<0.05). After treatment, the UPDRS Ⅱ and Ⅲ scores of the observation group were significantly lower than those of the control group(P<0.05). The serum CRP and IL-6 levels decreased after treatment in the two groups, and there was no significant difference between two groups(P>0.05). The incidence of adverse reactions during the treatment was not significantly different between the control group(11.63%) and the observation group(13.95%). Conclusion Pramexole treatment of Parkinson's disease after cerebral infarction is effective, which can reduce the level of serum inflammatory factors and improve patients' daily living ability and exercise capacity with high safety, thus it is suitable for clinical promotion.